Agreed. Shareholder psychology may cave in though at this offer price, as I mentioned above.Quote from Now is Now:
Roche will probably offer around high 90's then sweeten the pot to around the 105+ number.
They own a chunk of DNA anyway, but they are pretty desperate to improve their line of drugs as their own is dwindling. Both are great companies.
Quote from nitro:
Looks like I was wrong:
http://www.marketwatch.com/news/sto...996D8-74A1-4D72-8F14-6F22B1953106}&siteid=rss
DNA caved.